6 completed. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Digestive System Disease: new trials by email Literature Review of Digestive System Disease trials Research Report on Digestive System Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Growth Hormone in Decompensated Liver Cirrhosis Growth Hormone - Liver Cirrhosis, Fibrosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 96 | 2022-02-01 | 2025-12-16 |
| Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Ocoxin-Viusid® - Stomach Neoplasm, Gastrointestinal Neoplasms | Phase 2 | Completed | Catalysis SL | 45 | 2018-10-25 | 2024-02-07 |
| Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Ocoxin-Viusid - Colorectal Neoplasm, Intestinal Neoplasms | Phase 2 | Completed | Catalysis SL | 40 | 2018-10-25 | 2024-02-07 |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Nab-paclitaxel, Gemcitabine, Capecitabine - Adenocarcinoma, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 2018-06-21 | 2024-12-31 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease anti-Interferon-gamma monoclonal antibody - Crohn's Disease, Colitis | Phase 2 | Completed | Facet Biotech | 175 | 2002-03-01 | 2012-03-13 |
Digestive System Diseases (6) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Adenocarcinoma (2) · Colonic Diseases (2) · Colorectal Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Head and Neck Neoplasms (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma, Papillary (1)
Neoplasms by Site (3) · Neoplasms (2) · Atrophy (1) · Bronchial Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Gastroenteritis (1) · Genetic Diseases, Inborn (1) · Hepatic Insufficiency (1) · Inflammatory Bowel Diseases (1) · Liver Diseases (1) · Liver Failure (1) · Multiple Endocrine Neoplasia (1) · Muscular Atrophy (1)
Ocoxin (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Cisplatin (1) · Gemcitabine (1) · Growth Hormone (1) · Irinotecan (1) · pralsetinib (1)
Catalysis SL (2) · Facet Biotech (1) · Hoffmann-La Roche (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (3) · Cuba (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
Dung Le, MD (1) · Virendra Singh, DM (1)
PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723
2016 (1)